CIC
EW icon

Carnegie Investment Counsel’s Edwards Lifesciences EW Stock Holding History

Carnegie Investment Counsel’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$289K Hold
3,200
– – 0.01% 484
2026
Q1 		$256K Hold
3,200
– – 0.01% 506
2025
Q4 		$273K Hold
3,200
– – 0.01% 493
2025
Q3 		$249K Sell
3,200
-10
-0.3% -$781 ﹤0.01% 499
2025
Q2 		$251K Buy
3,210
+10
+0.3% +$746 0.01% 489
2025
Q1 		$221K Sell
3,200
-900
-22% -$64.4K 0.01% 470
2024
Q4 		$304K Sell
4,100
-120
-3% -$8.4K 0.01% 399
2024
Q3 		$278K Sell
4,220
-1,400
-25% -$102K 0.01% 408
2024
Q2 		$519K Hold
5,620
– – 0.02% 330
2024
Q1 		$537K Sell
5,620
-750
-12% -$63K 0.02% 346
2023
Q4 		$486K Buy
6,370
+701
+12% +$48.8K 0.02% 353
2023
Q3 		$393K Hold
5,669
– – 0.02% 377
2023
Q2 		$535K Sell
5,669
-250
-4% -$21.7K 0.02% 342
2023
Q1 		$490K Sell
5,919
-14
-0.2% -$1.1K 0.02% 358
2022
Q4 		$443K Buy
5,933
+14
+0.2% +$1.08K 0.02% 376
2022
Q3 		$489K Sell
5,919
-600
-9% -$57.7K 0.02% 335
2022
Q2 		$620K Buy
+6,519
New +$675K 0.03% 307
2022
Q1 		– Sell
-7,209
Closed -$934K – 495
2021
Q4 		$934K Sell
7,209
-1,200
-14% -$140K 0.03% 277
2021
Q3 		$952K Buy
8,409
+500
+6% +$57.1K 0.04% 251
2021
Q2 		$819K Sell
7,909
-75
-0.9% -$7.07K 0.03% 268
2021
Q1 		$668K Buy
7,984
+2,200
+38% +$186K 0.03% 284
2020
Q4 		$528K Buy
5,784
+699
+14% +$58K 0.02% 292
2020
Q3 		$406K Hold
5,085
– – 0.02% 310
2020
Q2 		$351K Hold
5,085
– – 0.02% 325
2020
Q1 		$320K Sell
5,085
-459
-8% -$33.1K 0.02% 318
2019
Q4 		$431K Sell
5,544
-228
-4% -$17.8K 0.02% 320
2019
Q3 		$423K Sell
5,772
-360
-6% -$25.3K 0.03% 318
2019
Q2 		$378K Buy
6,132
+504
+9% +$30.5K 0.02% 341
2019
Q1 		$359K Buy
+5,628
New +$321K 0.02% 343

Other funds holding EW

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Nordea Investment Management
Nordea Investment Management Stockholm, Sweden $123B AUM 38.85% 1-Year Est. Return
Universal-Beteiligungs- und Servicegesellschaft
Universal-Beteiligungs- und Servicegesellschaft Frankfurt Am Main, Germany $65.4B AUM 39.83% 1-Year Est. Return

Carnegie Investment Counsel's EW Position: Q2 2026 in Review

Carnegie Investment Counsel held its Edwards Lifesciences (EW) position steady in Q2 2026 at 3,200 shares worth $289K. The position accounts for 0.01% of the portfolio, ranked #484.

Carnegie Investment Counsel first reported a position in EW in Q1 2019 and has held it in 29 quarters since. The position peaked at $952K in Q3 2021. 774 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • Carnegie Investment Counsel held 3,200 shares of Edwards Lifesciences worth $289K as of Q2 2026.
  • Carnegie Investment Counsel left its Edwards Lifesciences share count unchanged in Q2 2026.
  • Edwards Lifesciences made up 0.01% of Carnegie Investment Counsel's portfolio in Q2 2026, its #484 holding.
  • Carnegie Investment Counsel first reported a position in Edwards Lifesciences in Q1 2019 and has held it in 29 quarters since.
  • Carnegie Investment Counsel's Edwards Lifesciences position peaked at $952K in Q3 2021.
  • 774 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Carnegie Investment Counsel's 13F filing for Q2 2026, filed 30 Jul 2026.